nach oben

Erschienen in:

01.10.2011 | Original Research Paper

Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting

verfasst von: T. I. Arefieva, T. L. Krasnikova, A. V. Potekhina, N. U. Ruleva, P. I. Nikitin, T. I. Ksenevich, B. G. Gorshkov, M. V. Sidorova, Zh. D. Bespalova, N. B. Kukhtina, S. I. Provatorov, E. A. Noeva, E. I. Chazov

Erschienen in: Inflammation Research | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective and design

The peptide from C-terminal domain of MCP-1 (Ingramon) has been shown to inhibit monocyte migration and possess anti-inflammatory activity in animal models of inflammation and post-angioplasty restenosis. Here, we investigate the effect of Ingramon treatment on blood levels of acute-phase reactants and chemokines in patients after coronary stenting and the mechanisms of Ingramon anti-inflammatory activity.

Subjects

Eighty-seven patients with ischemic heart disease (IHD) who faced the necessity of coronary angiography (CA) were enrolled. In 67 patients, one-stage coronary stenting was performed; 33 of them were treated with Ingramon in addition to standard therapy. Twenty patients underwent CA only.

Methods

High-sensitivity C-reactive protein (hsCRP) and fibrinogen blood levels were detected routinely. The chemokine concentration in plasma was measured by enzyme-linked immunosorbent assay (ELISA) or cytometric bead array-based immunoassay. Intracellular Ca²⁺ levels and cell surface integrin exposure were assayed by flow cytometry. MCP-1 dimerization was studied by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). MCP-1–heparin binding was assessed with a biosensor and ELISA.

Results and conclusions

Ingramon treatment was accompanied by less pronounced elevation of hsCRP and fibrinogen levels and decreased MCP-1 concentration in plasma in patients after coronary stenting. Ingramon had no effect on MCP-1 interaction with cell receptors or MCP-1 dimerization, but inhibited MCP-1 binding to heparin. The anti-inflammatory activity of the peptide may be mediated by an impaired chemokine interaction with glycosaminoglycans.

Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–8.PubMedCrossRef

Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. Engl J Med. 1998;338:436–45.CrossRef

Rollins BJ. Chemokines. Blood. 1997;90:909–28.PubMed

Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349–58.PubMedCrossRef

Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858–66.PubMedCrossRef

Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–81.PubMedCrossRef

Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999;143:205–11.PubMedCrossRef

Han KH, Han KO, Green SR, Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res. 1999;40:1053–63.PubMed

Mazzone A, De Servi S, Mazzucchelli I, Bossi I, Ottini E, Vezzoli M, et al. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart. 2001;85:571–5.PubMedCrossRef

10.

Hoio Y, Ikeda U, Takahashi M, Shimada K. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis. 2002;161:403–8.CrossRef

11.

Chazov EI, Bespalova JD, Arefieva TI, Kukhtina NB, Sidorova MV, Provatorov SI, Krasnikova TL. The peptide analogue of MCP-1 65–76 sequence is an inhibitor of inflammation. Can J Physiol Pharmacol. 2007;85:332–40.PubMedCrossRef

12.

Tung R, Kaul S, Diamond GA, Shah PK. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med. 2006;144:913–9.PubMed

13.

Juwana YB, Rasoul S, Ottervanger JP, Suryapranata H. Efficacy and safety of rapamycin as compared to paclitaxel-eluting stents: a meta-analysis. J Invasive Cardiol. 2010;22:312–6.PubMed

14.

Furukava Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306–14.

15.

Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327–34.PubMedCrossRef

16.

Sako H, Miura S, Iwata A, Nishikawa H, Kawamura A, Matsuo K, et al. Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. Intern Med. 2008;47:7–13.PubMedCrossRef

17.

Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation. 2009;120:1987–95.PubMedCrossRef

18.

Delhaye C, Maluenda G, Wakabayashi K, Ben-Dor I, Lemesle G, Collins SD, et al. Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. Am J Cardiol. 2010;105:826–32.PubMedCrossRef

19.

Saleh N, Svane B, Hansson L-O, Jensen J, Nilsson T, Danielsson O, Tornvall P. Response of serum C-reactive protein to percutaneous coronary intervention has prognostic value. Clin Chem. 2005;51:2124–30.PubMedCrossRef

20.

Reckless J, Tatalick LM, Grainger DJ. The pan-chemokine inhibitor NR58–3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo. Immunology. 2001;103:2244–54.CrossRef

21.

Sidorova MV, Molokoedov AS, Arefieva TI, Kuchtina NB, Krasnikova TL, Bespalova ZhD, Bushuev VN. Peptide fragments and structural analogues of chemokine MCP-1: synthesis and effect on the MCP-1-induced migration of mononuclear cells. Russ J Bioorg Chem. 2004;30:523–33.CrossRef

22.

Krasnikova TL, Arefieva TI, Melekhov MG, Kuchtina NB, Sidorova MV, Molokoedov AS, et al. The peptide of sequence 66–77 of monocyte chemotactic protein-1 (MCP-1) inhibits inflammation in experimental animals. Doklady Biol Sci. 2005;404:402–5.CrossRef

23.

Chazov EI, Krasnikova TL, Bespalova ZhD, Kuchtina NB, Melekhov MG, Arefieva TI, et al. Inhibition of migration of monocytes and granulocytes in vivo by the peptide corresponding to sequence 65-76 of monocyte chemotactic protein-1 (MCP-1). Doklady Biochem Biophys. 2006;411:339–41.CrossRef

24.

Sidorova MV, Molokoedov AS, Azmuko AA, Arefieva TI, Melekhov MG, Kukhtina NB, et al. Peptide fragment 66–77 of monocyte chemoattractant protein 1 and its retro-enantio analogue inhibit the migration of cells in vitro and in vivo. Russ J Bioorg Chem. 2006;32:146–53.CrossRef

25.

Kukhtina NB, Bashtrykov PP, Bespalova ZhD, Sidorova MV. Aref′eva TI, Krasnikova TL. Effects of synthetic monocyte chemotactic protein -1 fragment 65–76 on neointima formation after carotid artery ballon injury in rats. Neurosci Behav Physiol. 2009;39:153–9.PubMedCrossRef

26.

Zhang Y, Rollins BJ. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 function as a dimer. Mol Cell Biol. 1995;15:4851–5.PubMed

27.

Nikitin PI, Gorshkov BG, Nikitin EP, Ksenevich TI. Picoscope, a new label-free biosensor. Sens Actuators. 2005;111–112:500–4.

28.

Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood. 1991;78:1112–6.PubMed

29.

Vaddi K, Newton RC. Regulation of monocyte integrin expression by beta-family chemokines. J Immunol. 1994;153:4721–32.PubMed

30.

Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry. 1999;38:12959–68.PubMedCrossRef

31.

Lau EK, Paavola CD, Johnson Z, Gaudry JP, Geretti E, Borlat F, et al. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem. 2004;279:22294–305.PubMedCrossRef

32.

Krasnikova TL, Nikitin PI, Ksenevich TI, Gorshkov BG, Orlov AV, Sidorova MV, Azmuko AA, Arefieva TI, Mamochkina EN, Efremov EE, Bespalova ZhD. Effect of the C-terminal domain peptide fragment (65–76) of monocytic chemotactic protein-1 (MCP-1) on the interaction between MCP-1 and heparin. Dokl Biol Sci. 2010;433:289–92.PubMedCrossRef

33.

Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA. 1993;90:7158–62.PubMedCrossRef

34.

Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25:1679–87.PubMedCrossRef

35.

Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2002;106:2700–6.PubMedCrossRef

36.

Zhang Y, Ernst CA, Rollins BJ. MCP-1: structure/activity analysis. Methods. 1996;10:93–103.PubMedCrossRef

37.

Kim CH. Migration and fuction of Th 17 cells. Inflamm Allergy Drug Targets. 2009;8:221–8.PubMed

38.

Handel TM, Johnson Z, Crown SE, Lau EK, Sweeney M, Proudfoot AE. Regulation of protein function by glycosaminoglycans––as exemplified by chemokines. Annu Rev Biochem. 2005;74:385–410.PubMedCrossRef

39.

Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, et al. Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem. 1998;273:33157–65.PubMedCrossRef

40.

Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol. 1994;4:394–400.PubMedCrossRef

41.

Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA. 2003;100:1885–90.PubMedCrossRef

42.

Chakravarty L, Rogers L, Quach T, Breckenridge S, Kolattukudy PE. Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. J Biol Chem. 1998;273:29641–7.PubMedCrossRef

43.

Kuschert GS, Hoogewerf AJ, Proudfoot AE, Chung CW, Cooke RM, Hubbard RE, Wells TN, Sanderson PN. Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry. 1998;37:111193–201.CrossRef

44.

Rebeiz AG, Zoghbi E, Harb R, Youhanna S, Skouri HN, Dimassi A, Abou-Nader G, Nasrallah A, Sawaya J, Gharzuddine W, Alam S. Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. J Interv Cardiol. 2009;22(2):169–74.PubMedCrossRef

45.

Gaspardone A, Versaci F, Tomai F, Citone C, Proietti I, Gioffrè G, Skossyreva O. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006;97(9):1311–6.PubMedCrossRef

Titel: Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting
verfasst von: T. I. Arefieva
T. L. Krasnikova
A. V. Potekhina
N. U. Ruleva
P. I. Nikitin
T. I. Ksenevich
B. G. Gorshkov
M. V. Sidorova
Zh. D. Bespalova
N. B. Kukhtina
S. I. Provatorov
E. A. Noeva
E. I. Chazov
Publikationsdatum: 01.10.2011
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 10/2011
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-011-0356-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting